---
title: "AZN.UK (AZN.UK) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/AZN.UK/news.md"
symbol: "AZN.UK"
name: "AZN.UK"
parent: "https://longbridge.com/en/quote/AZN.UK.md"
datetime: "2026-05-20T15:57:58.681Z"
locales:
  - [en](https://longbridge.com/en/quote/AZN.UK/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/AZN.UK/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/AZN.UK/news.md)
---

# AZN.UK (AZN.UK) — Related News

### [AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension](https://longbridge.com/en/news/286904730.md)
*2026-05-19T11:34:58.000Z*
> AstraZeneca has received US approval for Baxfendy, a first-in-class aldosterone synthase inhibitor for adults with uncon

### [AstraZeneca Scores Key FDA Wins Across Cardiovascular And Oncology Portfolios](https://longbridge.com/en/news/286801629.md)
*2026-05-18T16:59:00.000Z*
> AstraZeneca received FDA approvals for Baxfendy, a hypertension treatment, and Enhertu for early HER2-positive breast ca

### [European Stocks Trend Higher in Monday Trading Despite Specter of Middle East War Reigniting](https://longbridge.com/en/news/286797154.md)
*2026-05-18T15:50:00.000Z*
> European stock markets rose on Monday, with the Stoxx Europe up 0.4% and Germany's DAX gaining 1.3%, amid rising oil pri

### [FDA approves Enhertu for two HER2-positive early breast cancer indications](https://longbridge.com/en/news/286740066.md)
*2026-05-18T07:49:17.000Z*
> A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings.

### [<![CDATA[FDA Expands Enhertu in Early HER2-Positive Breast Cancer]]>](https://longbridge.com/en/news/286780814.md)
*2026-05-18T13:11:58.000Z*
> The FDA has expanded the use of Enhertu (trastuzumab deruxtecan) for HER2-positive Stage II and III breast cancer, appro

### [AZN :FDA Approves ENHERTU For HER2-Positive Early Breast Cancer In Neoadjuvant And Adjuvant Settings](https://longbridge.com/en/news/286677080.md)
*2026-05-17T15:50:46.000Z*
> The FDA has approved AstraZeneca and Daiichi Sankyo's ENHERTU for neoadjuvant and adjuvant treatment of HER2-positive ea

### [Dow Jones Top Company Headlines at 3 AM ET: Anglo American to Sell Steelmaking Coal Assets to Dhilmar for Up to $3.875 Billion | AstraZeneca ...](https://longbridge.com/en/news/286730822.md)
*2026-05-18T07:30:25.000Z*
> Anglo American plans to sell its steelmaking coal assets to Dhilmar for up to $3.875 billion, completing its exit strate